trial · primary record
Ublituximab
Relapsing Multiple Sclerosis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 360 |
| Primary completion | 2028-12-31 |
| Primary endpoint | Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab |
| Registry ID | NCT07211633 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:51.835Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07211633
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.